Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Wednesday, 27'th Aug 2025
IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
3 Biotech Catalysts Present Major Opportunity
06:33pm, Monday, 25'th Aug 2025
For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability an
Top 2 Health Care Stocks That May Fall Off A Cliff In August
08:46am, Wednesday, 20'th Aug 2025
As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript
03:04am, Thursday, 07'th Aug 2025
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, Pre
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
07:01pm, Wednesday, 06'th Aug 2025
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.88 per share a year ago.
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
04:05pm, Wednesday, 06'th Aug 2025
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
05:00pm, Wednesday, 30'th Jul 2025
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 29'th May 2025
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:45am, Wednesday, 14'th May 2025
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Str
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off
12:28pm, Monday, 12'th May 2025
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demo
Tarsus to Participate in Upcoming Investor Conferences
05:00pm, Thursday, 08'th May 2025
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences:
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
06:27am, Monday, 05'th May 2025
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEM
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript
09:37pm, Thursday, 01'st May 2025
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Of
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
06:40pm, Thursday, 01'st May 2025
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago.
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
04:05pm, Thursday, 01'st May 2025
Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients
